Cargando…

Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy

BACKGROUND: Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of MPM is marked by a progressive transdifferentiation that converts well differe...

Descripción completa

Detalles Bibliográficos
Autores principales: Torricelli, F, Donati, B, Reggiani, F, Manicardi, V, Piana, S, Valli, R, Lococo, F, Ciarrocchi, Alessia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351128/
https://www.ncbi.nlm.nih.gov/pubmed/37460925
http://dx.doi.org/10.1186/s12943-023-01816-9
_version_ 1785074279523549184
author Torricelli, F
Donati, B
Reggiani, F
Manicardi, V
Piana, S
Valli, R
Lococo, F
Ciarrocchi, Alessia
author_facet Torricelli, F
Donati, B
Reggiani, F
Manicardi, V
Piana, S
Valli, R
Lococo, F
Ciarrocchi, Alessia
author_sort Torricelli, F
collection PubMed
description BACKGROUND: Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of MPM is marked by a progressive transdifferentiation that converts well differentiated epithelioid (E) cells into undifferentiated and pleomorphic sarcomatoid (S) phenotypes. Catching the way this transition takes place is necessary to understand how MPM develops and progresses and it is mandatory to improve patients’ management and life expectancy. Bulk transcriptomic approaches, while providing a significant overview, failed to resolve the timing of this evolution and to identify the hierarchy of molecular events through which this transition takes place. METHODS: We applied a spatially resolved, high-dimensional transcriptomic approach to study MPM morphological evolution. 139 regions across 8 biphasic MPMs (B-MPMs) were profiled using the GeoMx™Digital Spatial Profiler to reconstruct the positional context of transcriptional activities and the spatial topology of MPM cells interactions. Validation was conducted on an independent large cohort of 84 MPMs by targeted digital barcoding analysis. RESULTS: Our results demonstrated the existence of a complex circular ecosystem in which, within a strong asbestos-driven inflammatory environment, MPM and immune cells affect each other to support S-transdifferentiation. We also showed that TGFB1 polarized M2-Tumor Associated Macrophages foster immune evasion and that TGFB1 expression correlates with reduced survival probability. CONCLUSIONS: Besides providing crucial insights into the multidimensional interactions governing MPM clinical evolution, these results open new perspectives to improve the use of immunotherapy in this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-023-01816-9.
format Online
Article
Text
id pubmed-10351128
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103511282023-07-18 Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy Torricelli, F Donati, B Reggiani, F Manicardi, V Piana, S Valli, R Lococo, F Ciarrocchi, Alessia Mol Cancer Research BACKGROUND: Malignant Pleural Mesothelioma (MPM) is a dreadful disease escaping the classical genetic model of cancer evolution and characterized by wide heterogeneity and transcriptional plasticity. Clinical evolution of MPM is marked by a progressive transdifferentiation that converts well differentiated epithelioid (E) cells into undifferentiated and pleomorphic sarcomatoid (S) phenotypes. Catching the way this transition takes place is necessary to understand how MPM develops and progresses and it is mandatory to improve patients’ management and life expectancy. Bulk transcriptomic approaches, while providing a significant overview, failed to resolve the timing of this evolution and to identify the hierarchy of molecular events through which this transition takes place. METHODS: We applied a spatially resolved, high-dimensional transcriptomic approach to study MPM morphological evolution. 139 regions across 8 biphasic MPMs (B-MPMs) were profiled using the GeoMx™Digital Spatial Profiler to reconstruct the positional context of transcriptional activities and the spatial topology of MPM cells interactions. Validation was conducted on an independent large cohort of 84 MPMs by targeted digital barcoding analysis. RESULTS: Our results demonstrated the existence of a complex circular ecosystem in which, within a strong asbestos-driven inflammatory environment, MPM and immune cells affect each other to support S-transdifferentiation. We also showed that TGFB1 polarized M2-Tumor Associated Macrophages foster immune evasion and that TGFB1 expression correlates with reduced survival probability. CONCLUSIONS: Besides providing crucial insights into the multidimensional interactions governing MPM clinical evolution, these results open new perspectives to improve the use of immunotherapy in this disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-023-01816-9. BioMed Central 2023-07-17 /pmc/articles/PMC10351128/ /pubmed/37460925 http://dx.doi.org/10.1186/s12943-023-01816-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Torricelli, F
Donati, B
Reggiani, F
Manicardi, V
Piana, S
Valli, R
Lococo, F
Ciarrocchi, Alessia
Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
title Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
title_full Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
title_fullStr Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
title_full_unstemmed Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
title_short Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
title_sort spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351128/
https://www.ncbi.nlm.nih.gov/pubmed/37460925
http://dx.doi.org/10.1186/s12943-023-01816-9
work_keys_str_mv AT torricellif spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT donatib spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT reggianif spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT manicardiv spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT pianas spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT vallir spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT lococof spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy
AT ciarrocchialessia spatiallyresolvedhighdimensionaltranscriptomicssortsouttheevolutionofbiphasicmalignantpleuralmesotheliomanewparadigmsforimmunotherapy